Teva’s Christine Fox proposes sale of 28,229 shares
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Teva Pharmaceutical Industries Ltd. officer Christine Fox, identified as EVP and head of U.S. commercial, filed notice of a proposed sale of 28,229 ordinary shares, with an approximate sale date of November 20, 2026. The notice lists an aggregate market value of $1,095,297.87 and says the sale was to cover obligations under an established 10b5-1 plan adopted August 4, 2026. The securities table also lists 63,492 shares acquired through restricted share unit award vesting, with an acquisition date of November 20, 2023, and payment dated November 20, 2026.
Key Figures
Key Terms
10b5-1 plan regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
AI-generated analysis. How Rhea-AI works. Not financial advice.